๐ Replimune $REPL rockets +130% premarket โ FDA panel backed melanoma drug 10-3, final decision TODAY
Replimune $REPL is surging ~130% in premarket after the FDA advisory committee voted 10-3 last week that its RP1 melanoma therapy data is clinically meaningful. RP1 pairs with Bristol Myers Squibb's Opdivo for advanced melanoma patients who failed prior anti-PD-1 therapy โ and the FDA final approval decision is due today, August 2. A green light would be a landmark moment for oncolytic virus therapy. Not financial advice. Will REPL keep running on approval, or is this a classic buy-the-rumor setup?
โก 53 buzzing
417 views
๐ 0 subscribed
